Brown Shannon, Fletcher J Wesley, Fiala Katherine H
Department of Dermatology, Baylor Scott & White Health/Texas A&M Health Science Center College of Medicine, Temple, Texas.
Proc (Bayl Univ Med Cent). 2016 Jul;29(3):335-6. doi: 10.1080/08998280.2016.11929461.
Pityriasis rubra pilaris is a rare inflammatory disorder characterized by follicular papules on an erythematous base often exhibiting islands of unaffected skin, follicular plugging, and palmoplantar hyperkeratosis. While vitamin A deficiency and autoimmune reactions have been hypothesized as possible etiologies of this condition, pityriasis rubra pilaris-like eruptions secondary to medications are extremely rare. To our knowledge, only three other cases have been reported, and pityriasis rubra pilaris has never been reported in association with bevacizumab. We present a 70-year-old man who developed erythroderma both clinically and histologically consistent with pityriasis rubra pilaris 10 days after intravitreal injection of bevacizumab for age-related macular degeneration. As immune-modulating drugs grow in their application for a host of diseases, recognition of associated medication complications is important.
红皮病型毛发红糠疹是一种罕见的炎症性疾病，其特征为在红斑基础上出现毛囊丘疹，常伴有未受累皮肤岛、毛囊堵塞及掌跖角化过度。虽然维生素A缺乏和自身免疫反应被认为可能是该疾病的病因，但药物继发的红皮病型毛发红糠疹样皮疹极为罕见。据我们所知，仅另有3例报告，且从未有过贝伐单抗相关的红皮病型毛发红糠疹报告。我们报告1例70岁男性，在玻璃体内注射贝伐单抗治疗年龄相关性黄斑变性10天后，出现临床及组织学表现均符合红皮病型毛发红糠疹的红皮病。随着免疫调节药物在多种疾病中的应用不断增加，认识相关的药物并发症很重要。
